Juarez-Casso Fernando M, Crestanello Juan A
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA.
J Clin Med. 2023 Aug 15;12(16):5299. doi: 10.3390/jcm12165299.
Surgical aortic valve replacement (SAVR) has long been the standard treatment for severe symptomatic aortic stenosis (AS). However, transcatheter aortic valve replacement (TAVR) has emerged as a minimally invasive alternative; it was initially intended for high-risk patients and has now expanded its use to patients of all risk groups. While TAVR has demonstrated promising outcomes in diverse patient populations, uncertainties persist regarding its long-term durability and potential complications, raising the issue of the ideal lifetime management strategy for patients with AS. Therefore, SAVR continues to play an important role in clinical practice, particularly in younger patients with longer life expectancies, those with complex aortic anatomy who are unsuitable for TAVR, and those requiring concomitant surgical procedures. The choice between TAVR and SAVR warrants personalized decision-making, considering patient characteristics, comorbidities, anatomical considerations, and overall life expectancy. A multidisciplinary approach involving an experienced heart team is crucial in the preoperative evaluation process. In this review, we aimed to explore the current role of surgical management in addressing aortic valve stenosis amidst the expanding utilization of less invasive transcatheter procedures.
外科主动脉瓣置换术(SAVR)长期以来一直是重度症状性主动脉瓣狭窄(AS)的标准治疗方法。然而,经导管主动脉瓣置换术(TAVR)已成为一种微创替代方案;它最初是针对高危患者设计的,现在其应用范围已扩大到所有风险组别的患者。虽然TAVR在不同患者群体中已显示出有前景的结果,但其长期耐久性和潜在并发症仍存在不确定性,这就引发了AS患者理想的终身管理策略问题。因此,SAVR在临床实践中继续发挥重要作用,特别是在预期寿命较长的年轻患者、解剖结构复杂而不适合TAVR的患者以及需要同期进行外科手术的患者中。TAVR和SAVR之间的选择需要个性化决策,要考虑患者特征、合并症、解剖因素以及总体预期寿命。在术前评估过程中,由经验丰富的心脏团队采用多学科方法至关重要。在本综述中,我们旨在探讨在侵入性较小的经导管手术应用不断扩大的情况下,外科治疗在解决主动脉瓣狭窄方面的当前作用。